Skip to main content

Neumann Mark's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Mar 13, 2023

Accession no.
0001209191-23-018286
Filed
Mar 13, 2023
Trade date
Mar 9-13, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $539.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Neumann MarkCIK 0001756211Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 9, 2023Common StockAGrant or awardAcquired+16,708$0.00$065,907Direct
Mar 10, 2023Common StockSSaleDisposed−6,750$43.50−$293,62559,157Direct
Mar 10, 2023Common StockSSaleDisposed−1,800$42.74−$76,93257,357Direct
Mar 10, 2023Common StockMOption exerciseAcquired+7,344––64,701Direct
Mar 13, 2023Common StockSSaleDisposed−3,335$45.10−$150,408.561,366Direct
Mar 13, 2023Common StockSSaleDisposed−423$44.05−$18,633.1560,943Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2023Common StockMOption exerciseDisposed−7,344$0.00$014,690Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)